Levodopa-carbidopa intestinal gel infusion (LCIG) in Parkinson disease with genetic mutations

ConclusionsOverall, we observed a significant benefit in terms of motor complications in our cohort, including patients carrying genetic mutations/variants. Due to the small sample and limited number of patients carrying genetic mutations/variants, no definitive conclusions can be drawn yet on the genotype impact on LCIG outcome. A careful selection of patients, regardless of the genetic background, is pivotal for an optimal outcome of LCIG.
Source: Neurological Sciences - Category: Neurology Source Type: research